

10/ 638,848

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:25:08 ON 22 APR 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:25:17 ON 22 APR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7
 DICTIONARY FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.


 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10638848.str



chain nodes :

11 12 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18

chain bonds :

5-21 8-12 9-11 12-13

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 13-14 13-18 14-15 15-16
 16-17 17-18

exact/norm bonds :

1-2 1-6 2-3 3-4 3-10 4-5 5-6 5-21 8-12 9-10 9-11

exact bonds :

2-7 7-8 8-9 12-13

10/ 638,848

normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

SAMPLE SEARCH INITIATED 15:25:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 245 TO ITERATE

100.0% PROCESSED 245 ITERATIONS 40 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3961 TO 5839
PROJECTED ANSWERS: 421 TO 1179

L2 40 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 15:26:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5837 TO ITERATE

100.0% PROCESSED 5837 ITERATIONS 955 ANSWERS
SEARCH TIME: 00.00.01

L3 955 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
161.33	161.54

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:26:07 ON 22 APR 2005

10/ 638,848

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Apr 2005 VOL 142 ISS 18
FILE LAST UPDATED: 21 Apr 2005 (20050421/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 16 L3

=> d l4 1- ibib abs hitstr



YOU HAVE REQUESTED DATA FROM 16 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:120672 CAPLUS
 DOCUMENT NUMBER: 142:198094
 TITLE: Preparation of pyrimidopyrimidines as protein kinase inhibitors
 INVENTOR(S): Sim, Taebo; Lee, Hyun Soo; Ren, Pingda; Ding, Qiang; Wang, Xia; Uno, Tetsuo; Zhang, Guobao; Liu, Yi; Li, Bing; Li, Lintong; Gray, Nathaniel; You, Shuli
 PATENT ASSIGNEE(S): IRM LLC, Bermuda
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011597	A2	20050210	WO 2004-US24764	20040729
WO 2005011597	A3	20050324		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
 GI US 2003-491133P P 20030729

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The invention provides a novel class of compds. I [$n = 0-4$; $Z = N, CH$; $R_1 = H, alkyl, arylalkyl, hydroxy, alkoxy, etc.$; $R_2, R_3 = H, alkyl, or R_1$ and R_2 together form O or S ; $R_4 = H, OH, NH_2, alkyl, etc.$; $R_5 = alkyl, alkenyl, alkoxy, etc.$; $R_6 = NR_1R_2Y(O)R_3, Y(O)NR_1R_2R_3$ (wherein $Y = C, P(O), S(O)$; $R_12 = H, alkyl$; $R_13 = aryl, heteroaryl, cycloalkyl, etc.$)], pharmaceutical compns. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with abnormal

or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Fli3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases. E.g., a multi-step synthesis of II, starting from 4-amino-2-methylsulfonylpyrimidine-5-carbonitrile, was given. The compds. I show a percentage inhibition of greater than 50% against the mentioned above kinases at 10 μM .

IT

839705-51-OP 839705-52-1P 839705-53-2P
 839705-54-3P 839705-55-4P 839705-56-5P
 839705-57-6P 839705-58-7P 839705-59-8P
 839705-60-1P 839705-61-2P 839705-62-3P
 839705-63-4P 839705-64-5P 839705-65-6P
 839705-66-7P 839705-67-8P 839705-69-0P
 839705-70-3P 839705-71-4P 839705-72-5P
 839705-73-6P 839705-74-7P 839705-75-8P
 839705-76-9P 839705-77-0P 839705-78-1P
 839705-79-2P 839705-80-5P 839705-81-6P
 839705-82-7P 839705-83-8P 839705-84-9P
 839705-85-0P 839705-86-1P 839705-87-2P
 839705-88-3P 839705-89-4P 839705-90-7P

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

839705-91-8P 839705-92-9P 839705-93-0P
 839705-94-1P 839705-95-2P 839705-96-3P
 839705-97-4P 839705-98-5P 839705-99-6P
 839706-00-7P 839706-01-8P 839706-02-9P
 839706-03-5P 839706-04-6P 839706-05-7P
 839706-06-8P 839706-07-9P 839706-08-0P
 839706-09-1P 839706-10-4P 839706-11-5P
 839706-12-6P 839706-13-7P 839706-14-8P
 839706-15-9P 839706-16-0P 839706-17-1P
 839706-18-2P 839706-19-3P 839706-20-6P
 839706-21-7P 839706-22-8P 839706-23-9P
 839706-24-0P 839706-25-1P 839706-26-2P
 839706-27-3P 839706-28-4P 839706-29-5P
 839706-30-8P 839706-31-9P 839706-32-0P
 839706-33-1P 839706-34-2P 839706-35-3P
 839706-36-4P 839706-37-5P 839706-38-6P
 839706-39-7P 839706-40-0P 839706-41-1P
 839706-42-2P 839706-43-3P 839706-44-4P
 839706-45-5P 839706-46-6P 839706-47-7P
 839706-48-8P 839706-49-9P 839706-50-2P
 839706-51-3P 839706-52-4P 839706-53-5P
 839706-54-6P 839706-55-7P 839706-56-8P
 839706-57-9P 839706-58-0P 839706-59-1P
 839706-60-4P 839706-61-5P 839706-62-6P
 839706-63-7P 839706-64-8P 839706-65-9P
 839706-66-0P 839706-67-1P 839706-68-2P
 839706-69-3P 839706-70-6P 839706-71-7P
 839706-72-8P 839706-73-9P 839706-74-0P
 839706-75-1P 839706-76-2P 839706-77-3P
 839706-78-4P 839706-79-5P 839706-80-6P
 839706-81-9P 839706-82-0P 839706-83-1P
 839706-84-2P 839706-85-3P 839706-86-4P
 839706-87-5P 839706-88-6P 839706-89-7P
 839706-90-0P 839706-91-1P 839706-93-3P
 839706-94-4P 839706-96-6P 839706-97-7P
 839706-98-8P 839706-99-9P 839707-00-5P
 839707-01-6P 839707-02-7P 839707-03-8P
 839707-04-9P 839707-05-0P 839707-06-1P
 839707-07-2P 839707-08-3P 839707-09-4P
 839707-10-7P 839707-11-8P 839707-12-9P
 839707-13-0P 839707-14-1P 839707-15-2P
 839707-16-3P 839707-17-4P 839707-18-5P
 839707-19-6P 839707-20-9P 839707-21-0P
 839707-22-1P 839707-23-2P 839707-24-3P
 839707-25-4P 839707-26-5P 839707-27-6P
 839707-28-7P 839707-29-8P 839707-30-1P
 839707-31-2P 839707-32-3P 839707-33-4P
 839707-34-5P 839707-35-6P 839707-36-7P
 839707-37-8P 839707-38-9P 839707-39-0P
 839707-40-3P 839707-41-4P 839707-42-5P
 839707-44-7P 839707-45-8P 839707-46-9P
 839707-47-0P 839707-48-1P 839707-49-2P
 839707-50-5P 839707-51-6P 839707-52-7P
 839707-53-8P 839707-54-9P 839707-55-0P
 839707-56-1P 839707-57-2P 839707-58-3P
 839707-59-4P 839707-60-7P 839707-61-8P
 839707-62-9P 839707-63-0P 839707-64-1P
 839707-65-2P 839707-66-3P 839707-67-4P
 839707-68-5P 839707-69-6P 839707-70-9P
 839707-71-0P 839707-72-1P 839707-73-2P


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

839707-74-3P 839707-75-4P 839707-76-5P
 839707-77-6P 839707-78-7P 839707-79-8P
 839707-80-1P 839707-81-2P 839707-82-3P
 839707-83-4P 839707-84-5P 839707-85-6P
 839707-86-7P 839707-87-8P 839707-89-0P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrimidopyrimidines as protein kinase inhibitors)


RN 839705-51-0 CAPLUS
 CN Benzamide, N-[3-[[[3-(4-dihydro-1-methyl-2-oxo-7-[[phenylmethyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)]-(9CI) (CA INDEX NAME)



RN 839705-52-1 CAPLUS
 CN Benzamide, N-[3-[[[3-(4-dihydro-1-methyl-2-oxo-7-[[phenylmethyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)]-(9CI) (CA INDEX NAME)




RN 839705-53-2 CAPLUS
 CN Benzamide, N-[3-[[[3-(4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)]-(9CI) (CA INDEX NAME)



RN 839705-54-3 CAPLUS
 CN Benzamide, N-[3-[[[3-(4-dihydro-1-methyl-7-[[3-[[4-methyl-1-piperazinyl]methyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

CF₃

RN 839705-55-4 CAPLUS
CN Benzamide, N-[3-[7-[[3-(aminosulfonyl)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-56-5 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[[3-(2-hydroxyethyl)phenyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-57-6 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839705-61-2 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-methyl-1-piperazinyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-62-3 CAPLUS
CN Benzamide, N-[3-[7-[[3-(formylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-63-4 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-64-5 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-58-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-phenylhydrazino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-59-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[[3-[(hydroxyacetyl)amino]phenyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-60-1 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4H-1,2,4-triazol-4-ylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, N-[3-[7-(cyclopropylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-65-6 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[[2-hydroxyethyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-66-7 CAPLUS
CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-(2-hydroxyethyl)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-67-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[2-[(1-methylethyl)amino]ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-CF₃


RN 839705-69-0 CAPLUS

CN Benzoic acid, 3-[[5,6,7,9-tetrahydro-8-methyl-6-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 839705-70-3 CAPLUS

CN Benzamide, N-[3-[7-(cyclobutylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-71-4 CAPLUS

CN Benzamide, N-[3-[7-(cyclopentylamino)-1,4-dihydro-1-methyl-2-




RN 839705-75-8 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(2-methyl-2-propenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-76-9 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(3-(2-oxo-1-pyrrolidinyl)propyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-77-0 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-72-5 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[[[(1S)-2-hydroxy-1-methylethyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839705-73-6 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839705-74-7 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-propenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-NMe₂


RN 839705-78-1 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[3-[7-[[3-[(dimethylamino)methyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-79-2 CAPLUS

CN Benzamide, N-[3-[7-[[3-[(2-(dimethylamino)ethyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-80-5 CAPLUS

CN Benzamide, N-[3-[7-[[3-[(2-aminoethyl)amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


-CF₃

RN 839705-81-6 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[2-(methylamino)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-82-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839705-86-1 CAPLUS
CN Benzamide, N-[3-[7-[[4-(2-aminoethyl)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-87-2 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-(4-morpholinylmethyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-88-3 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[[3-(1H-imidazol-1-yl)propyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-89-4 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

-CF₃

RN 839705-83-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

-CF₃

RN 839705-84-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[2-(methylamino)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-85-0 CAPLUS
CN Benzamide, N-[3-[7-[[4-(2-aminoethyl)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[3-[2-(1-piperazinyl)ethyl]phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-CF₃

RN 839705-90-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[4-[2-(1-piperazinyl)ethyl]phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


-CF₃

RN 839705-91-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-((3-methyl-5-isoxazolyl)amino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839705-92-9 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-2-oxo-7-[[3-(1-piperazinylmethyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-93-0 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-2-oxo-7-[[4-(1-piperazinyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-94-1 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-2-oxo-7-[[4-(1-piperazinyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839705-98-5 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-2-oxo-7-[[6-(2-methyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-99-6 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-2-oxo-7-[[6-(2-ethenyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-00-2 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-2-oxo-7-[[6-(trifluoromethyl)-3-pyridinyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839705-95-2 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-96-3 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-97-4 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-01-3 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


-CF3

RN 839706-02-4 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-03-5 CAPLUS
 CN Benamide, N-[3-[[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-04-6 CAPLUS
CN Benzamide, N-[3-[7-[(4-fluorophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-05-7 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-06-8 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-10-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-11-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-N-methyl-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-12-6 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-7-[(4-fluorophenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-07-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-08-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 839706-09-1 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4-piperidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-13-7 CAPLUS
CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-ethenylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-14-8 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(3-methyl-5-isoxazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-15-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-(4-morpholinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 839706-16-0 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-CF₃

RN 839706-17-1 CAPLUS


CN Benzamide, N-[3-[1-cyclopropyl-7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-18-2 CAPLUS


CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-22-8 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-2-oxo-7-[[4-(trifluoromethyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-23-9 CAPLUS

CN Benzamide, N-[3-[7-(ethylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-24-0 CAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-19-3 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-7-[(4,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-20-6 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-21-7 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[4-(trifluoromethyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839706-25-1 CAPLUS

CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-26-2 CAPLUS

CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-27-3 CAPLUS


CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-28-4 CAPLUS


CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-ethylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-29-5 CAPLUS

CN Benamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-30-8 CAPLUS

CN Benamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(3-(2-oxo-1-pyrrolidinyl)propyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-31-9 CAPLUS

CN Benamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-32-0 CAPLUS

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-36-4 CAPLUS

CN Benamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-37-5 CAPLUS

CN Benamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-38-6 CAPLUS


CN Benamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-morpholinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-39-7 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Benamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(3-(2-oxo-1-pyrrolidinyl)propyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-33-1 CAPLUS

CN Benamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-34-2 CAPLUS

CN Benamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2,4-dioxypyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-35-3 CAPLUS

CN Benamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2,4-dioxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Benamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-40-0 CAPLUS

CN Benamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-41-1 CAPLUS


CN Benamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-morpholinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-42-2 CAPLUS

CN Benamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-43-3 CAPLUS
 CN Benzamide, N-[3-[[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)]- (9CI) (CA INDEX NAME)




RN 839706-44-4 CAPLUS
 CN Benzamide, N-[3-[[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-[(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-47-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-1,2-dihydro-2-oxo-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-48-8 CAPLUS
 CN Benzamide, N-[3-[[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 839706-49-9 CAPLUS
 CN Benzamide, N-[3-[[1,4-dihydro-7-(methylamino)-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-45-5 CAPLUS
 CN Benzamide, N-[3-[[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-46-6 CAPLUS
 CN Benzamide, N-[3-[[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[(4-morpholinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-50-2 CAPLUS
 CN Benzamide, N-[3-[[7-(ethylamino)-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-51-3 CAPLUS
 CN Benzamide, N-[3-[[7-(cyclopropylamino)-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839706-52-4 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methyl-2-propenyl)amino]-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-53-5 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-54-6 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxo-7-(4-(4-morpholinyl)phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-57-9 CAPLUS

CN Benzamide, N-[3-[7-(cyclopropylamino)-1,4-dihydro-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-58-0 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-59-1 CAPLUS

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-55-7 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-(methylamino)-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-56-8 CAPLUS

CN Benzamide, N-[3-[7-(ethylamino)-1,4-dihydro-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-60-4 CAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(1-methylethyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-61-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 839706-62-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-N-methyl-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839706-63-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-64-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)



RN 839706-65-9 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, N-ethyl-3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)



RN 839706-66-0 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-N,N-dimethyl-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-70-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-[[1,3-dimethyl-1H-pyrazol-5-yl]amino]-3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 839706-71-7 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-[[4,6-dimethyl-3-pyridinyl]amino]-3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 839706-72-8 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-N-methyl-7-[[6-methyl-3-pyridinyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-67-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, N-cyclopropyl-3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)



RN 839706-68-2 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 839706-69-3 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-(ethylamino)-3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-73-9 CAPLUS

CN Benzamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[[4-ethyl-1-piperazinyl]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-74-0 CAPLUS

CN Benzamide, N-[3-(7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[[4-ethyl-1-piperazinyl]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-75-1 CAPLUS

CN Benzamide, N-[3-(1-ethyl-1,4-dihydro-7-[[6-methyl-3-pyridinyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[[4-ethyl-1-piperazinyl]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-76-2 CAPLUS

CN Benzamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-77-3 CAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-78-4 CAPLUS

CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-82-0 CAPLUS

CN Acetamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)





RN 839706-83-1 CAPLUS

CN Acetamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-84-2 CAPLUS

CN Acetamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-79-5 CAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(1-methylethyl)amino]-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-80-8 CAPLUS

CN Benzamide, N-[3-[7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-81-9 CAPLUS

CN Acetamide, N-[3-[1-ethyl-1,4-dihydro-7-[(4-(4-morpholinyl)phenyl)amino]-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)


RN 839706-85-3 CAPLUS

CN Acetamide, N-[3-[7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-86-4 CAPLUS

CN Benzamide, N-[3-[1-ethyl-7-[(1-ethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-87-5 CAPLUS


CN Benzamide, N-[3-[7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-88-6 CAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido(4,5-d)pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-89-7 CAPLUS
CN Benzamide, N-[3-[7-[(4,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-90-0 CAPLUS
CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-91-1 CAPLUS
CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-93-3 CAPLUS

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 839706-97-7 CAPLUS
CN Benzamide, N-[3-[7-[(5-[(dimethylamino)methyl]-2-thiazolyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 839706-98-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


-CF₃

RN 839706-99-9 CAPLUS
CN Benzamide, N-[3-[7-[[4-[(dimethylamino)methyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(2-methyl-4-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-94-4 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[(4-methyl-1-piperazinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-96-6 CAPLUS
CN Benzamide, N-[3-[7-[[4-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-00-5 CAPLUS
CN Benzamide, N-[3-[7-[(3-cyanophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-01-6 CAPLUS
CN Benzamide, N-[3-[7-[(5-cyano-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-02-7 CAPLUS
CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-03-8 CAPLUS

CN Benzanide, N-[3-[(7-[(4,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-04-9 CAPLUS


CN Benzanide, N-[3-[(7-[(4-methoxy-3-pyridinyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-05-0 CAPLUS


CN Benzanide, N-[3-[(7-[(4-methoxy-3-pyridinyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-09-4 CAPLUS

CN Benzanide, N-[3-[(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-10-7 CAPLUS


CN Benzanide, N-[3-[(7-amino-1,4-dihydro-1,4-dimethyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-11-8 CAPLUS


CN Benzanide, N-[3-[(7-amino-1,4-dihydro-1,4-dimethyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-06-1 CAPLUS

CN Benzanide, N-[3-[(7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-07-2 CAPLUS


CN Benzanide, N-[3-[(7-[(2,4-dimethyl-5-thiazolyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-08-3 CAPLUS


CN Benzanide, N-[3-[(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-12-9 CAPLUS

CN Benzanide, N-[3-[(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-13-0 CAPLUS

CN Benzanide, N-[3-[(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-14-1 CAPLUS


CN Benzanide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)

RN 839707-15-2 CAPLUS
CN Benamide, N-[3-[[7-(ethylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-16-3 CAPLUS
CN Benamide, N-[3-[[7-[[4-(diethylamino)ethoxy]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


CF₃

RN 839707-17-4 CAPLUS
CN Benamide, N-[3-[[7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 839707-21-0 CAPLUS
CN Benamide, N-[3-[[1-ethyl-1,4-dihydro-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-22-1 CAPLUS
CN Benamide, N-[3-[[7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-23-2 CAPLUS
CN Benamide, N-[3-[[1-ethyl-1,4-dihydro-7-[[2-methyl-2-propenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-24-3 CAPLUS
CN Benamide, N-[3-[[7-[[3-(diethylamino)propyl]amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-18-5 CAPLUS
CN Benamide, N-[3-[[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-19-6 CAPLUS
CN Benamide, N-[3-[[1-ethyl-1,4-dihydro-7-[[3-(4-morpholinyl)propyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-20-9 CAPLUS
CN Benamide, N-[3-[[1-ethyl-1,4-dihydro-7-[[4-(4-morpholinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 839707-25-4 CAPLUS
CN Benamide, N-[3-[[7-[[4-(diethylamino)butyl]amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-26-5 CAPLUS
CN Benamide, N-[3-[[7-[[3-(dimethylamino)phenyl]amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-27-6 CAPLUS
CN Benamide, N-[3-[[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-nitro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-28-7 CAPLUS
CN Benamide, 3-amino-N-[3-[[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-29-8 CAPLUS

CN Benzamide, N-[3-[7-[[3-[(2S)-2-amino-1-oxopropyl]amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

CF3

RN 839707-30-1 CAPLUS

CN Benzamide, N-[3-[7-[[3-[(2S)-2-amino-3-methyl-1-oxobutyl]amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

CF3

RN 839707-33-4 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-pyrimidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839707-34-5 CAPLUS


CN Benzamide, N-[3-[7-[(5,6-dimethyl-1,2,4-triazin-3-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 1-B



RN 839707-31-2 CAPLUS

CN Benzamide, N-[3-[7-[[6-[3-(dimethylamino)-1-pyrrolidinyl]-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-32-3 CAPLUS

CN Benzamide, N-[3-[7-[[6-[2-(dimethylamino)ethyl]methylamino]-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839707-35-6 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(pyrazinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 839707-36-7 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-methyl-5-isothiazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-37-8 CAPLUS


CN Benzamide, N-[3-[7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-38-9 CAPLUS

CN Benzamide, N-[3-[7-[(1-ethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 839707-39-0 CAPLUS

CN Benamide, N-[3-[[[6-(2-(dimethylamino)-1-methylethoxy)-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-CF₃

RN 839707-40-3 CAPLUS


CN Benamide, N-[3-[[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 839707-45-8 CAPLUS

CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-46-9 CAPLUS

CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-47-0 CAPLUS

CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

PAGE 1-A




PAGE 1-B

-CF₃


RN 839707-41-4 CAPLUS

CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-43-6 CAPLUS


CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-44-7 CAPLUS


CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 839707-48-1 CAPLUS

CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-49-2 CAPLUS

CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-50-5 CAPLUS


CN Benamide, N-[3-[[[6-(2-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 839707-51-6 CAPLUS
 CN Benzamide, N-[3-[(1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-52-7 CAPLUS
 CN Benzamide, N-[3-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-53-8 CAPLUS
 CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 839707-54-9 CAPLUS
 CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-58-3 CAPLUS
 CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-59-4 CAPLUS
 CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-morpholinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-60-7 CAPLUS
 CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-55-0 CAPLUS
 CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 839707-56-1 CAPLUS
 CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-5-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-57-2 CAPLUS
 CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-61-8 CAPLUS
 CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-[(diethylamino)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-62-9 CAPLUS
 CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-63-0 CAPLUS
 CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-64-1 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-65-2 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-66-3 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-70-9 CAPLUS
 CN Benamide, 4-[(cyclopropylamino)methyl]-N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-71-0 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-72-1 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-(1-pyrrolidinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-67-4 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-(4-morpholinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-68-5 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-69-6 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-73-2 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-74-3 CAPLUS
 CN Benamide, 4-[(diethylamino)methyl]-N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-75-4 CAPLUS
 CN Benamide, N-[3-([1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839707-76-5 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-77-6 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-78-7 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(1-pyrrolidinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-79-8 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-83-4 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-84-5 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-85-6 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-[3-(dimethylamino)-1-pyrrolidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-80-1 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-81-2 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-[3-(dimethylamino)-1-pyrrolidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-82-3 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-86-7 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-87-8 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-95-8 CAPLUS

CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)







IT 839707-96-9P 839707-97-0P 839707-98-1P
 839707-99-2P 839708-00-8P 839708-01-9P
 839708-02-0P 839708-03-1P 839708-04-2P
 839708-05-3P 839708-06-4P 839708-07-5P
 839708-08-6P 839708-09-7P 839708-10-0P
 839708-11-1P 839708-13-3P 839708-14-4P
 839708-15-5P 839708-16-6P 839708-17-7P
 839708-18-8P 839708-19-9P 839708-20-2P
 839708-21-3P 839708-22-4P 839708-23-5P
 839708-24-6P 839708-25-7P 839708-26-8P
 839708-27-9P 839708-28-0P 839708-29-1P
 839708-30-4P 839708-31-5P 839708-32-6P
 839708-33-7P 839708-34-8P 839708-35-9P
 839708-36-0P 839708-37-1P 839708-38-2P
 839708-39-3P 839708-40-6P 839708-41-7P
 839708-42-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidines as protein kinase inhibitors)
 RN 839707-96-9 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



RN 839708-00-8 CAPLUS
 CN Benzamide, N-[3-[7-[[2-fluoro-3-(trifluoromethyl)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-01-9 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-02-0 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(methylsulfonyl)amino]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

NMe₂


RN 839707-97-0 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-98-1 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(aminocarbonyl)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-99-2 CAPLUS
 CN Benzamide, N-[3-[7-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-03-1 CAPLUS
 CN Benzamide, N-[3-[7-[[1,4-dihydro-1-methyl-7-[[3-[(methylsulfonyl)amino]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


Me

RN 839708-04-2 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(dimethylamino)propyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-05-3 CAPLUS
 CN Acetamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839708-06-4 CAPLUS
CN Benzanide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 839708-07-5 CAPLUS
CN Benzanide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 839708-08-6 CAPLUS
CN Benzanide, N-[3-[1,4-dihydro-1-methyl-7-[(4-methyl-2-thiazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839708-13-3 CAPLUS
CN Benzanide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-14-4 CAPLUS
CN Benzanide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-15-5 CAPLUS
CN Benzoic acid, 3-[[[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839708-09-7 CAPLUS
CN 4-Thiazoleacetic acid, 2-[[[5,6,7,8-tetrahydro-8-methyl-6-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839708-10-0 CAPLUS
CN Benzanide, N-[3-[7-[[3-(aminophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-11-1 CAPLUS
CN Benzanide, N-[3-[7-[[3-(aminophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839708-16-6 CAPLUS
CN Benzanide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-2,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-17-7 CAPLUS
CN Benzanide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-18-8 CAPLUS
CN Benzanide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-19-9 CAPLUS
CN Benamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-20-2 CAPLUS
CN Benamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-21-3 CAPLUS
CN Benamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 839708-25-7 CAPLUS
CN Benamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

-CF₃


RN 839708-26-8 CAPLUS
CN Benamide, N-[3-[1,4-dihydro-1-methyl-7-[[2-(4-methyl-1-piperazinyl)-4-pyridinyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-27-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-methyl-N-[3-[[5,6,7,8-tetrahydro-8-methyl-6-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 839708-22-4 CAPLUS
CN Benamide, N-[3-[1,4-dihydro-7-[[3-(hydroxyphenyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-23-5 CAPLUS
CN Benamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-(4-morpholinylsulfonyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-24-6 CAPLUS
CN Benamide, N-[3-[7-[[3-[[dimethylamino]methyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 839708-28-0 CAPLUS
CN Benamide, N-[3-[7-[[3-[[2R]-1-ethyl-2-pyrrolidinyl]methyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839708-29-1 CAPLUS
CN Benamide, N-[3-[7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-30-4 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-31-5 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-32-6 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(dimethylamino)-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-33-7 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839708-36-0 CAPLUS
 CN Benzamide, 3-[2-(dimethylamino)-N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-37-1 CAPLUS
 CN Benzamide, 3-[2-(dimethylamino)ethoxy]-N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-38-2 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(2-(4-morpholinyl)ethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B


-CF₃

RN 839708-34-8 CAPLUS
 CN Benzamide, N-[3-[7-[[3-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 839708-35-9 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(5-pyrimidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A




PAGE 1-B



RN 839708-39-3 CAPLUS
 CN Benzamide, 3-[[2-(dimethylamino)ethyl]amino]-N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-40-6 CAPLUS
 CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-41-7 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 CN 1H-Pyrazole-5-carboxamide, N-[3-[[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-1-methyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-42-8 CAPLUS
 CN Benzamide, N-[3-[[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 839708-47-3P 839708-48-4P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrimidopyrimidines as protein kinase inhibitors).
 RN 839708-47-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[3-(dimethylamino)phenyl]amino]-3,4-dihydro-1-methyl-3-(2-methyl-5-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 839708-48-4 CAPLUS

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2004:857176 CAPLUS
 DOCUMENT NUMBER: 141:350187
 TITLE: Preparation of pyrimido compounds having antiproliferative activity
 INVENTOR(S): Chen, Yi; Dermatakis, Apostolos; Liu, Jin-jun; Luk, Kin-chun; Michoud, Christophe; Rossman, Pamela Lorenson
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 55 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204427	A1	20041014	US 2004-817697	20040402
WO 2004089955	A1	20041021	WO 2004-EP3447	20040401

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPL. INFO.: US 2003-461694P P 20030410
 OTHER SOURCE(S): MARPAT 141:350187
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are methods for preparing novel pyrimido compds. I [R1 = H, (un)substituted-alkyl, -cycloalkyl, -alkenyl, etc.; R2 and R3 independently = H, halo, (un)substituted-alkyl, -alkenyl, etc.; R4-8 independently = H, hydroxyalkyl, alkoxyalkyl, halo, etc.] that are selective inhibitors of both KDR and FGFR kinases. Thus, e.g., II was prep'd via acylation of trans-4-(tert-butylidimethylsilyloxy)cyclohexylamine (preparation given) with phosgene and subsequent cyclization with (2,4-dichloropyrimidin-5-ylmethyl) (4-methoxyphenyl)amine followed by desilylation. The IC50 values for I were as follows: KDR less than 0.50 µM; FGFR less than 2 µM. These compds. and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compns. containing these compds. and methods of treating cancer.

IT 774232-16-5P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-1-yl]propionitrile
 774232-32-5P, 4-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]piperidine-1-carboxylic acid tert-butyl ester
 774232-33-6P, trans-1-[4-(tert-Butyldimethylsilyloxy)cyclohexyl]-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 774232-34-7P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(5-amino-2-methylphenyl)-7-[[[3-(dimethylamino)phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 d]pyrimidin-1-yl]piperidine-1-carboxylic acid tert-butyl ester
 774232-35-8P, cis-1-[3-(tert-Butyldimethylsilyloxy)cyclopentyl]-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 774232-44-9P 774232-45-0P 774232-48-3P
 774232-50-7P 774232-55-2P 774232-58-5P
 774232-60-9P 774232-61-0P 774232-62-1P
 774232-63-2P 774232-64-3P 774232-68-7P
 774232-71-2P

RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prepn. of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)

RN 774232-16-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-propanenitrile, 3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774232-32-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774232-33-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[trans-4-[[[1,1-dimethylethyl]dimethylsilyloxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774232-34-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 774232-35-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R,3S)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774232-48-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774232-50-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R,3R)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 774232-55-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S,3S)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-44-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-1-[(trans-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-45-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(trans-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).




RN 774232-58-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[[[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-60-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[[[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-61-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[[[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-62-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[[[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-7-[(4-fluoro-3-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 774232-68-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-methyl-3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-71-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R,3R)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]-3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-63-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[[[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-64-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[[[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Relative stereochemistry.

IT 774231-91-3P, 1-Cyclohexyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-92-4P, 3-(4-Methoxyphenyl)-7-phenylamino-1-piperidin-4-yl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-93-5P, 1-(trans-4-Hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-94-6P, 3-(4-Methoxyphenyl)-7-phenylamino-1-piperidin-3-yl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-95-7P, 1-Cyclopentyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-96-8P, 1-(1,1-Dioxo-tetrahydrothiophen-3-yl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-97-9P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]piperidine-1-carboxaldehyde 774231-98-0P, 3-(4-Methoxyphenyl)-7-phenylamino-1-(tetrahydro-pyran-4-yl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-99-1P, 1-(trans-3-Hydroxycyclopentyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-00-7P, 1-(cis-3-Hydroxycyclopentyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-01-8P, (R)-3-(4-Methoxyphenyl)-7-phenylamino-1-(tetrahydrofuran-3-yl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-02-9P, (R)-3-(4-Methoxyphenyl)-7-phenylamino-1-(pyrrolidin-3-yl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-03-0P, trans-7-(4-Fluorophenylamino)-1-(3-hydroxycyclopentyl)-3-(4-methoxyphenyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-04-1P, trans-3-(2-Fluoro-4-methoxyphenyl)-1-(3-hydroxycyclopentyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-05-2P, (S)-(+)-1-(2-Hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-06-3P, (S)-(+)-7-(4-Fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-07-4P, trans-3-(2-Fluoro-4-methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(4-methoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-08-5P, trans-3-(2-Fluoro-4-methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(3,4-dimethoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-09-6P, trans-3-(4-Methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(3,4-dimethoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-10-7P, trans-3-(4-Methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(4-methoxyphenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-11-8P, (S)-(+)-3-(2-Fluoro-4-methoxyphenyl)-7-(4-fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-12-1P, (S)-(+)-3-(2-Fluoro-4-methoxyphenyl)-1-(2-hydroxy-1-methylethyl)-7-(4-methoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-13-2P, (R)-(-)-1-(2-Hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-14-3P, 3-(4-Methoxyphenyl)-1-methyl-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-15-4P, 1-(2-Methoxyethoxymethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-17-6P 774232-18-7P, (R)-1-(2-Hydroxypropyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-19-8P 774232-21-2P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-1-yl]propionamide 774232-22-3P, (S)-(+)-1-(2-Hydroxypropyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-23-4P 774232-24-5P 774232-25-6P 774232-26-7P 774232-27-8P 774232-28-9P

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 774232-29-0P, (R)-3-(4-Ethylphenyl)-7-(4-fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 774232-30-3P, trans-3-(4-Ethylphenyl)-7-(4-fluorophenylamino)-1-(3-hydroxycyclopentyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 774232-31-4P, 1-Cyclopropylmethyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)


RN 774231-91-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclohexyl-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 774231-92-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 774231-93-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774231-97-9 CAPLUS

CN 1-Piperidinecarboxaldehyde, 3-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 774231-98-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 774231-99-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774231-94-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(3-piperidinyl)- (9CI) (CA INDEX NAME)



RN 774231-95-7 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 774231-96-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-00-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-01-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-[(3R)-tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 774232-02-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-03-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-04-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 774232-07-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-08-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-09-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-05-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 774232-06-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-10-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-11-0 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 774232-12-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 774232-13-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 774232-14-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774232-19-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 774232-21-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774232-22-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(2S)-2-hydroxypropyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 774232-15-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(2-methoxyethoxy)methyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774232-17-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 774232-18-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(2R)-2-hydroxypropyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-23-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-24-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 774232-25-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-26-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-27-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-30-3 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3S)-3-hydroxycyclopentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-31-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-(cyclopropylmethyl)-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




IT 774232-74-5P 774232-75-6P 774232-78-9P

774232-79-0P 774232-80-3P 774232-86-9P

774232-90-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-28-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-29-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 774232-74-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-75-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-methylethyl]-7-[(4-fluorophenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-78-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-methylethyl]-7-[(4-fluorophenyl)amino]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-79-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-80-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-86-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(2R)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]propyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-90-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(2S)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]propyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2004:701815 CAPLUS

DOCUMENT NUMBER:

141:185104

TITLE:

Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions

INVENTOR(S):

Rudolph, Amy E.; Rocha, Ricardo; Carretero, Oscar

PATENT ASSIGNEE(S):

USA

SOURCE:

U.S. Pat. Appl., 107 pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167197	A1	20040826	US 2004-788220	20040226
WO 2004075852	A2	20040910	WO 2004-US5609	20040226
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DM, EC, EC, EE, EE, EG, EG, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004075857	A2	20040910	WO 2004-US5799	20040226
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DM, EC, EC, EE, EE, EG, EG, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.:

US 2003-450529P

P 20030226


AB This invention is directed generally to a method for treating a pathol. condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor (or "ACE inhibitor") for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor. This invention is further directed generally to pharmaceutical compns. comprising a p38-kinase inhibitor, and more specifically to compns. comprising the above-described combinations.

IT 335652-44-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (compos., combinations, and methods for treating cardiovascular
 conditions and other assoc. conditions)
 RN 335652-44-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-
 [(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:633921 CAPLUS
 DOCUMENT NUMBER: 141:174079
 TITLE: Preparation of 2-aminopyridines as cdk4 inhibitors
 INVENTOR(S): Bivarsal, Cathlin Marie; McNamara, Dennis Joseph;
 Repine, Joseph Thomas; Toogood, Peter Laurence;
 Vanderveil, Scott Norman; Warmus, Joseph Scott
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065378	A1	20040805	WO 2004-1891	20040109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CP, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HA, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ				
US 2004236084	A1	20041125	US 2004-759749	20040116
PRIORITY APPL. INFO.: MARPAT 141:174079			US 2003-440805P	P 20030117
OTHER SOURCE(S):				

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A1 = (un)substituted monocyclic or bicyclic heteroaryl; R1 = H, alk(en)yl, acyl, aryloxy, carbonyl, alkoxy, carbonyl, trialkylsilyl; X, Y = independently H, halo, CN, alkyl, alkoxy, carbonyl, alkoxy, carbonyl, NO2, OR and derivs., NH2 and derivs., SO2NH2 and derivs., etc.; W = H, halo, cycloalkoxy/halo/hydroxy/alkyl, alkenyl, alkynyl, CN, NO2, SH and derivs., NH2 and derivs., SO2NH2 and derivs., heteroaryl, etc.; WCCX, or WCCY = (un)substituted aryl ring containing up to three heteroatoms; and their pharmaceutically acceptable salts, esters, amides, or prodrugs] were prepared as cyclin-dependent kinases 4 (cdk4) inhibitors. For example, II was prepared by cyclocondensation of guanidine III with 2-cyclopentyl-6-hydroxyethyl-3-methoxycyclohex-2-en-1-one, dehydrogenation, and BOC-deprotection. II selectively inhibited cdk4 over cdk2 with IC50 values of 0.004 µM and 1.7 µM, resp. Thus, I and their formulations are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis (no data).

IT 733039-10-6P, 3-Benzyl-1-cyclopentyl-7-[(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-yl)amino]-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for

L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 treating cell proliferative disorders)
 RN 733039-10-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3,4-dihydro-3-(phenylmethyl)-7-[[5-(1-piperidinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:412946 CAPLUS
 DOCUMENT NUMBER: 140:423694
 TITLE: Preparation of pyrimidopyrimidinone derivatives having anticancer activity
 INVENTOR(S): Dermatakis, Apostolos; Kabat, Marek Michal; Luk, Kin-Chun; Rossman, Pamela Loreen; So, Sung-Sau
 F. Hoffmann-La Roche A.-G., Switz.
 PATENT ASSIGNEE(S): PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041822	A1	20040521	WO 2003-EP11896	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HA, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110773	A1	20040610	US 2003-689438	20031020
US 2005075272	A1	20050407	US 2003-689235	20031020
PRIORITY APPL. INFO.: MARPAT 140:423694			US 2002-423670P	P 20021104
OTHER SOURCE(S):				

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = H, (substituted)alkyl, (substituted)acyl, (substituted)heteroaryl, (substituted)heterocycle, (substituted)cycloalkyl, (substituted)alkenyl, (substituted)alkynyl; R2, R3, R4 = H, halo, COR10, CO2R10, CONR10R11, SOR10, SO2R10, CN, or NO2; R5, R6, R7, R8 = H, (substituted)alkyl, (substituted)amino, OH, halo, etc.; R9 = H, -COOC(R12R13COR14, or COR15; R10 = H, (substituted)alkyl, (substituted)cycloalkyl, (substituted)heterocycle, etc.; R12, R13 = H, alkyl; R14 = (substituted)alkyl; R15 = H, alkyl or cycloamines with 3-7 atoms] were prepared as anti-proliferative agents for the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. For example, reaction of 7-chloro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-3,4-dihydro-1H-pyrimido[4,5-d]-2-one (preparation given) with aniline yielded compound II. The latter showed inhibition of KDR, FGFR, EGFR and PDGFR with IC50 < 10 µM.


IT 690991-80-1P 690991-82-3P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidopyrimidinone derivs. having anticancer activity)

RN 690991-80-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 690991-82-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 690991-78-7P 690991-94-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidopyrimidinone derivs. having anticancer activity)
RN 690991-78-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-94-7 CAPLUS
CN Benzonitrile, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 690991-88-9 CAPLUS
CN Benzamide, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 690991-90-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 4-ethyl-3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-92-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




IT 690991-84-5P 690991-86-7P 690991-88-9P
690991-90-3P 690991-92-5P 690991-96-9P
690991-98-1P 690992-00-8P 690992-02-0P
690992-04-2P 690992-06-4P 690992-12-2P
690992-14-4P 690992-16-6P 690992-17-7P
690992-19-9P 690992-21-3P 690992-23-5P
690992-25-7P 690992-27-9P 690992-29-1P
690992-30-4P 690992-32-6P 690992-34-8P
690992-36-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrimidopyrimidinone derivs. having anticancer activity)
RN 690991-94-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1,3-bis(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-86-7 CAPLUS
CN Benzonitrile, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 690991-96-9 CAPLUS
CN Benzamide, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 690991-98-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-(1-methylethyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690992-00-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-5-methoxyphenyl)-3,4-dihydro-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 690992-02-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 690992-04-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 690992-06-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 690992-17-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-19-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 690992-12-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-1-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 690992-14-4 CAPLUS
 CN Acetamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-5-methyl-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 690992-16-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690992-21-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-23-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 690992-25-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 690992-27-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chlorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 690992-34-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chlorophenyl)-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690992-36-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chloro-2-fluorophenyl)-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 690992-65-5P 690992-70-2P 690992-72-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 690992-29-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chloro-2-fluorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690992-30-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chlorophenyl)-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690992-32-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chloro-2-fluorophenyl)-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


(Reactant or reagent)
 (prepn. of pyrimidopyrimidinone derivs. having anticancer activity)
 RN 690992-65-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690992-70-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-72-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:412345 CAPLUS
DOCUMENT NUMBER: 140:423693
TITLE: Preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer
INVENTOR(S): Luk, Kin-Chun; Rossman, Pamela Loreen; Scheiblich, Stefan; So, Sung-Sau
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041821	A1	20040521	WO 2003-EP311892	20031027
W:	AF, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SH, TD, TG			
US 2004110773	A1	20040610	US 2003-689438	20031020
US 2005075272	A1	20050407	US 2003-689235	20031020
PRIORITY APPLN. INFO:			US 2002-423670P	P 20021104
OTHER SOURCE(S):		MARPAT 140:423693		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB NovPyrimido compds. I (R1 = H, alkyl, substituted alkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkenyl, alkynyl; R2,R3,R4 independently = H, amine, alkoxy, sulfanyl, alkyl, cycloalkyl, alkenyl, alkynyl; R5, R6, R7, R8 independently = H, lower alkyl, amine, OH, alkoxy, sulfanyl, halogen, ketone, ester, amide, sulfonyl, CN; R9 = H, diester, ketone), that are selective inhibitors of the Src family of tyrosine kinases are prepared for the treatment of breast, colon, pancreatic, and hepatic cancers. Thus, 1-(2,4-dichloro-pyrimidin-5-yl)-ethanol was treated with phosphorus oxybromide and diisopropyl amine to give 2,4-dichloro-5-(1-bromomethyl)-pyrimidine which was treated with p-anisidine, potassium carbonate, and potassium iodide to give the corresponding amine. The above amine was reacted with 3-cyanophenyl isocyanate in toluene to give II. II was reacted with acetic acid 2-(3-amino-phenyl)-Et ester, followed by treatment with potassium carbonate in methanol to give III. III showed and IC50 of less than 1.0 μ M against Src tyrosine kinase. Also disclosed are pharmaceutical compns. containing these compds. and the use for

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

treating cancer.
IT 690995-25-6P 690995-29-0P 690995-31-4P
690995-33-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)
RN 690995-25-6 CAPLUS
CN Benzonitrile, 3-[7-[[3-[2-(dimethylamino)ethyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
(CA INDEX NAME)




RN 690995-29-0 CAPLUS
CN Benzonitrile, 3-[3,4-dihydro-7-[[3-[2-(hydroxyethyl)phenyl]amino]-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
(CA INDEX NAME)




RN 690995-31-4 CAPLUS
CN Benzonitrile, 3-[7-[[3-[2-(diethylamino)ethyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
(CA INDEX NAME)

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 690995-33-6 CAPLUS
CN Benzonitrile, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-[[3-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
(CA INDEX NAME)



IT 690995-35-8P 690995-36-9P 690995-37-0P
690995-38-1P 690995-39-2P 690995-40-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)


RN 690995-35-8 CAPLUS
CN Benzamide, 3-[7-[[3-[2-(diethylamino)ethyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
(CA INDEX NAME)



L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 690995-36-9 CAPLUS

CN Benzamide, 3-[7-[[3-[2-(dimethylamino)ethyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 690995-37-0 CAPLUS


CN Benzamide, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-[[3-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 690995-38-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1,4-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)

RN 690995-24-5 CAPLUS

CN Benzonitrile, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-[[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 690995-39-2 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI) (CA INDEX NAME)



RN 690995-40-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 690995-23-4P 690995-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
[preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer]

RN 690995-23-4 CAPLUS

CN Benzonitrile, 3-[7-[[3-[2-(acetyloxy)ethyl]phenyl]amino]-3,4-dihydro-3-(4-

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:372873 CAPLUS

DOCUMENT NUMBER: 140:391294

TITLE: Preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives as inhibitors of src family tyrosine kinases

INVENTOR(S): Cai, Jianping; Dimoudis, Nikolaos; Honold, Konrad; Luk, Kin-Chun; Scheiblich, Stefan; Sudergat, Hilke; Tiefenthaler, Georg; Tonn, Oliver

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 31 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087600	A1	20040506	US 2003-697543	20031030
WO 2004041823	A1	20040521	WO 2003-EP12203	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: EP 2002-24573 A 20021104


OTHER SOURCE(S): CASREACT 140:391294; MARPAT 140:391294

GI




AB The title compds. [I; R1 = H, alkyl, aryl, etc.; R2 = halo, CN, CF3; R3 = halo, OH, CN, etc.; n = 0-2; R4 = H, alkyl, alkoxy, CN; A = (un)substituted 2,3-dihydrobenzo[1,4]dioxin-6-yl, benzodioxane-6-yl, 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-7-yl, etc.] which are protein kinase inhibitors, in particular they inhibit the src family tyrosine kinases, and therefore useful for the treatment of diseases mediated by src tyrosine kinases, including cell proliferative disorders such as cancer, were prepared. Thus, reacting 3-(2-bromophenyl)-3,4-dihydro-7-methanesulfonyl-1-methylpyrimido[4,5-d]pyrimidin-2(1H)-one with 2-hydroxymethyl-6-amino-1,4-benzodioxane (preparation given) afforded 3-(2-bromophenyl)-7-(2-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-ylamino)-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2(1H)-one which


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 showed IC50 of 7.5 nM against src kinase, and IC50 of 6.3 nM against lck kinase. The pharmaceutical compn. contg. the compd. I is claimed.
 IT 686756-87-6P 686756-91-2P 686756-98-9P
 686757-21-1P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)
 RN 686756-87-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686756-91-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2-(chloromethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686756-98-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686757-02-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2-((dimethylamino)methyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-06-2 CAPLUS
 CN Spiro[1,3-benzodioxole-2,4'-piperidine], 1'-acetyl-5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 686757-10-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-methyl-7-((spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

686757-21-1 CAPLUS
 RN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



IT 686756-95-6P 686757-02-8P 686757-06-2P
 686757-10-8P 686757-14-2P 686757-17-5P
 686757-25-5P 686757-29-9P 686757-33-5P
 686757-37-9P 686757-40-4P 686757-44-8P
 686757-48-2P 686757-55-1P 686757-60-8P
 686757-65-3P 686757-70-0P 686757-73-3P
 686757-78-8P 686757-82-4P 686757-88-0P
 686757-93-7P 686759-58-0P 686759-62-6P
 686759-66-0P 686759-70-6P 686759-74-0P
 686759-78-4P 686759-82-0P 686759-86-4P
 686759-92-2P 686759-99-9P 686760-03-2P
 686760-07-6P 686760-11-2P 686760-14-5P
 686760-18-9P 686760-22-5P 686760-26-9P
 686760-30-5P 686760-34-9P 686760-37-2P
 686760-41-8P 686760-47-4P 686760-51-0P
 686760-55-4P 686760-59-8P 686760-63-4P
 686760-67-8P 686760-70-3P 686760-74-7P
 686760-78-1P 686760-82-7P 686760-92-8P
 686760-96-3P 686761-00-2P 686761-07-9P
 686761-11-5P 686761-18-2P 686761-21-7P
 686761-25-1P 686761-29-5P 686761-36-4P
 686766-23-4P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)

RN 686756-95-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-2-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

686757-14-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[2,3-dihydro-4,4-dioxido-1,4-benzoxathin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-17-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-4,4-dioxido-1,4-benzoxathin-6-yl]amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 686757-25-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-[[3-methoxy-4-methyl-1-oxido-4H-1,4-benzothiazin-7-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-29-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[3,4-dihydro-4-methyl-1,1-dioxido-2H-1,4-benzothiazin-7-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-33-5 CAPLUS
CN 1H-isindole-1,3(2H)-dione, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-(2-hydroxy-1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 686757-37-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-1-methyl-7-[(spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 686757-40-4 CAPLUS
CN 1H-isindole-1,3(2H)-dione, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





RN 686757-60-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl-, (9CI) (CA INDEX NAME)



RN 686757-65-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-5-methoxyphenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathin-6-yl)amino]-3,4-dihydro-1-methyl-, (9CI) (CA INDEX NAME)




RN 686757-70-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathin-6-yl)amino]-3-(2-fluoro-6-methoxyphenyl)-3,4-dihydro-1-methyl-, (9CI) (CA INDEX NAME)




● HCl

RN 686757-44-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,3-dioxido-1,3-benzoxathiol-5-yl)amino]-3,4-dihydro-1-methyl-, (9CI) (CA INDEX NAME)




RN 686757-48-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-(1,3-benzodioxol-5-ylamino)-3-(2-bromophenyl)-3,4-dihydro-1-methyl-, (9CI) (CA INDEX NAME)



RN 686757-55-1 CAPLUS
CN 1H-isindole-1,3(2H)-dione, 5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-methyl-, (9CI) (CA INDEX NAME)


RN 686757-73-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathin-6-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686757-78-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686757-82-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686757-88-0 CAPLUS
CN Benzonitrile, 2-[[7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathin-6-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-3-fluoro-, (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686757-93-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(1'-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-58-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1,3-benzodioxol-5-ylamino)-3-(2,4-dichlorophenyl)-3,4-dihydro-1-(4-methoxyphenyl)-] (9CI) (CA INDEX NAME)




RN 686759-62-6 CAPLUS
CN Benzoxathiin, 2-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686759-78-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(1'-ethylspiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-82-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-[(1'-2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-86-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-7-[(1'-2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686759-66-0 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxylic acid, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 686759-70-6 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine], 1'-acetyl-5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 686759-74-0 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxylic acid, 5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 686759-92-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-methyl-7-[(1'-methylspiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]- (9CI) (CA INDEX NAME)



RN 686759-99-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-1-methyl-7-[(1'-methylspiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 686760-03-2 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-acetonitrile, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 686760-07-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-5-methoxyphenyl)-3,4-dihydro-1-methyl-7-(spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686760-11-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-14-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-3-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-18-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[2-(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686760-34-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-3-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686760-37-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[2,3-dihydro-3-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-41-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[2,3-dihydro-3-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-47-4 CAPLUS


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686760-22-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[3-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-26-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[3-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-30-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2-(cyclopropylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686760-51-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-55-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-59-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-1,4-benzoxathiin-7-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686760-63-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-67-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4,4-dioxido-1,4-benzoxathin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-70-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686760-92-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-96-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-00-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686760-74-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-78-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-82-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 686761-07-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-11-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-18-2 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 686761-21-7 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 696761-25-1 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 696761-29-5 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 696761-36-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[3,3-dioxido-1,3-benzoxathiol-5-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:162462 CAPLUS
DOCUMENT NUMBER: 140:199340
TITLE: Preparation of pyrimidopyrimidinone derivatives having antiproliferative activity
INVENTOR(S): Chen, Yi; Daniewicz, Andrzej; Roberts, Harris, William; Kabat, Marek Michal; Liu, Emily; Aljun, Liu, Jin-jun; Luk, Kin-chun; Michoud, Christophe
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004038995	A1	20040226	US 2003-623972	20030721
WO 2004018472	A2	20040304	WO 2003-EP8744	20030807
WO 2004018472	A3	20040429		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MV, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: MARPAT 140:199340
OTHER SOURCE(S):
GI




AB The title I [R1 = H, COR4, COOCHR5OCOR4; R2, R3 = H or OR5; R4 = alkyl, or alkyl substituted by NR5R6, SR5, OR5, (substituted)aryl, heteroaryl, heterocycle; R5, R6 = H, alkyl or NR5R6 form a ring optionally including one or more addnl. N or O] were prepared as selective inhibitors of both KDR and FGFR kinases and are selective against LCK. Thus, reaction of 7-chloro-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]-2-one (preparation given) with aniline yielded compound II (R1, R2, R3 = H).


The




RN 696766-23-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
latter showed inhibition of KDR, FGFR, EGFR and PDGFR with IC50 = 0.044, 0.076, 0.360, and 0.130 μM, resp.
IT 663198-02-5P 663198-06-9P 663198-08-1P 663198-09-2P 663198-20-7P 663198-27-4P 663198-33-2P 663198-34-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidopyrimidinone derivs. having antiproliferative activity)
RN 663198-02-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 663198-06-9 CAPLUS
CN Glycine, N,N-dimethyl-, [[[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)




RN 663198-08-1 CAPLUS
CN Acetamide, 2-amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 663198-07-0

CMF C27 H24 N6 O3



CM 2


CRN 64-19-7

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN C2 H4 O2




RN 663198-09-2 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663198-20-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl- (9CI) (CA INDEX NAME)




RN 663198-27-4 CAPLUS
CN Benzenepropanamide, α-amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 663198-03-6 CAPLUS
CN Acetamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 663198-04-7 CAPLUS
CN Propanamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 663198-05-8 CAPLUS
CN Carbanic acid, phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (acetyloxy)methyl ester (9CI) (CA INDEX NAME)




RN 663198-10-5 CAPLUS
CN Benzenepropanamide, α-amino-4-hydroxy-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 663198-33-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl]- (9CI) (CA INDEX NAME)




RN 663198-34-3 CAPLUS
CN Acetamide, N-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



IT 663198-03-6P 663198-04-7P 663198-05-8P
663198-10-5P 663198-11-6P 663198-12-7P
663198-13-6P 663198-15-0P 663198-16-1P
663198-17-2P 663198-18-3P 663198-19-4P
663198-21-9P 663198-22-9P 663198-23-0P
663198-24-1P 663198-25-2P 663198-26-3P
663198-28-5P 663198-30-9P 663198-31-0P
663198-32-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidopyrimidinone derivs. having antiproliferative activity)


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 663198-11-6 CAPLUS
CN Hexanamide, 2,6-diamino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 663198-12-7 CAPLUS
CN 1H-Indole-3-propanamide, α-amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 663198-13-8 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 663198-15-0 CAPLUS
CN 4-Piperidinecarboxylic acid, [[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]oxy]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 663198-14-9
CMF C33 H32 N6 O6



RN 663198-19-4 CAPLUS
CN Acetamide, N-(4-hydroxyphenyl)-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 663198-21-8 CAPLUS
CN Acetamide, N-(4-methoxyphenyl)-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 663198-22-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)-, mono(methanesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 663198-02-5
CMF C25 H21 N5 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 663198-16-1 CAPLUS
CN Pentanamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 663198-17-2 CAPLUS
CN Butanamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 663198-18-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(4-hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)




RN 663198-23-0 CAPLUS
CN Glycine, N,N-dimethyl-, [[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]oxy]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 663198-24-1 CAPLUS
CN Acetamide, 2-amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 663198-25-2 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 663198-09-2
CMF C30 H30 N6 O3 S

Absolute stereochemistry.

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 663198-26-3 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 663198-28-5 CAPLUS
CN Benzenepropanamide, α-amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (αS)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Absolute stereochemistry.



● HCl

RN 663198-32-1 CAPLUS
CN Propanamide, 2-amino-3-hydroxy-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 663198-38-7P 663198-39-8P 663198-41-2P
663198-42-3P 663198-44-5P 663198-46-7P
663198-47-8P 663198-48-9P 663198-50-3P
663198-51-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidopyrimidinone derivs. having antiproliferative activity)
RN 663198-38-7 CAPLUS
CN Carbamic acid, phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, chloromethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 663198-30-9 CAPLUS
CN Pentanamide, 2-amino-4-methyl-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 663198-29-6
CMF C31 H32 N6 O3

Absolute stereochemistry.




CM 2

CRN 64-19-7
CMF C2 H4 O2


RN 663198-31-0 CAPLUS
CN Pentanamide, 2-amino-4-methyl-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-, monoacetate (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 663198-39-8 CAPLUS
CN Carbamic acid, [(1S)-3-(methylthio)-1-[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]propyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663198-41-2 CAPLUS
CN Carbamic acid, [(1S)-2-oxo-2-[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]-1-(phenylmethyl)ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 663198-42-3 CAPLUS
 CN Carbamic acid, [(1S)-3-methyl-1-[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]butyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663198-44-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[[4-(1,1-dimethylethoxy)phenyl]methyl]-2-oxo-2-[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663198-46-7 CAPLUS


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]phenylamino]ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663198-50-3 CAPLUS
 CN Carbamic acid, [(1R)-3-(methylthio)-1-[[[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]phenylamino]carbonyl]propyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663198-51-4 CAPLUS
 CN 1,4-Piperidinedicarboxylic acid, 1-[(1,1-dimethylethyl)-4-[[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]oxy]methyl] ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Carbamic acid, [(1S)-1-[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]-1,5-pentanedyl]bis-, bis(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663198-47-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[(1H-indol-3-ylmethyl)-2-oxo-2-[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663198-48-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[(1,1-dimethylethoxy)methyl]-2-oxo-2-[[[5,6,7,8-

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:80385 CAPLUS

DOCUMENT NUMBER: 140:146153

TITLE: Preparation of pyrimidopyrimidinones as kinase inhibitors

INVENTOR(S): Chivikas, Connolly Cleo J.; Deur, Christopher James; Hamby, James Marino; Hoyer, Denton Wade; Limberakis, Chris; Reed, Jessica Elizabeth; Schroeder, Mel Conrad; Taylor, Clarke

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 44 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004019210	A1	20040129	US 2003-621983	20030717
WO 2004011465	A1	20040205	WO 2003-1B3359	20030721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 140:146153


GI

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



I



II

AB This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimidopyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula I [A = O, NH2, mono(or di)alkylamino, NHCONHR12 (wherein R12 = alkyl, alkylencycloalkyl); B, C, D = CH, N (with the proviso that C and D are not both N); R1 = alkyl (optionally substituted by CO2H), (un)substituted Ph, CH2Ph, piperidinyl, etc.; R2 = H, Cl, F; R3 = H, Cl, F (at least one of R2 or R3 = F); R4 = H, OH, OMe, OEt (if R4 = H, R2 and R3 is not H); R5 = OMe, OEt; R6 = H, alkyl-NH2, O-alkyl-NH2, etc.] that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediates for their synthesis, as well as pharmaceutical compns. and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer (no biol. data given). Synthesis of 35 title compds. I is described. E.g., a multi-step synthesis of II was given.

IT 651734-15-5P 651734-16-6P 651734-35-9P

651734-43-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of pyrimidopyrimidinones as kinase inhibitors)

RN 651734-15-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN


(Continued)



RN 651734-16-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[[(4S,5S)-5-(hydroxymethyl)-2-phenyl-1,3-dioxolan-4-yl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-35-9 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)

RN 651734-43-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 651734-14-4P 651734-17-7P 651734-18-8P

651734-19-9P 651734-20-2P 651734-21-3P

651734-22-4P 651734-23-5P 651734-24-6P

651734-25-7P 651734-26-8P 651734-27-9P

651734-28-0P 651734-29-1P 651734-30-4P

651734-31-5P 651734-32-6P 651734-33-7P

651734-34-8P 651734-36-0P 651734-38-2P

651734-39-3P 651734-40-6P 651734-41-7P

651734-42-8P 651734-45-1P 651734-46-2P

651734-47-3P 651734-48-4P 651734-49-5P


651734-50-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidinones as kinase inhibitors)

RN 651734-14-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-17-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dimethoxyphenyl)-3,4-dihydro-7-[[[(2S,3S)-2,3,4-trihydroxybutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-18-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 651734-19-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651734-23-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-24-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 651734-25-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651734-20-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2-hydroxypropyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-21-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 651734-22-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopropyl-7-[[[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651734-26-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[[[(2R,3R)-2,3-dihydroxybutyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-27-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[[[(2R)-2,3-dihydroxypropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

RN 651734-28-0 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-amino-2,3-dihydroxybutyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-29-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2S,3S)-2,3,4-trihydroxybutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-30-4 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

RN 651734-34-8 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R,3R)-2,3-dihydroxybutyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-36-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 651734-31-5 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[2S,3S)-4-amino-2,3-dihydroxybutyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-32-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-bis(2-hydroxyethyl)amino]propyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-33-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[[2S)-2,3-dihydroxypropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


RN 651734-38-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-1-(4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 651734-37-1

CMF C19 H22 F2 N6 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 651734-39-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 651734-40-6 CAPLUS

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(4-hydroxybutyl)amino]- (9CI) (CA INDEX NAME)



RN 651734-41-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(2S)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-42-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651734-45-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-1-(4-piperidiny)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 651734-44-0
 CMF C20 H24 F2 N6 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 651734-46-2 CAPLUS

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R)-2,3-dihydroxypropyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-47-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(4-(diethylamino)butyl)amino]-3-(3-ethoxy-2,6-difluorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-48-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(2R)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651734-49-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 651734-50-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 651735-18-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:300721 CAPLUS
 DOCUMENT NUMBER: 134:326540
 TITLE: Preparation of alkylamino substituted bicyclic nitrogen heterocycles for pharmaceutical use as inhibitors of p38 protein kinase
 INVENTOR(S): Dunn, James Patrick; Fisher, Lawrence Emerson; Goldstein, David Michael; Harris, William; Hill, Christopher Huw; Smith, Ian Edward David; Welch, Teresa Rosanne
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
 SOURCE: PCT Int. Appl., 177 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029042	A1	20010426	WO 2000-EP10088	20001013
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2388142	AA	20010426	CA 2000-2388142	20001013
BR 2000015243	A	20020716	BR 2000-15243	20001013
EP 1228070	A1	20020807	EP 2000-967864	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200201057	T2	20020923	TR 2002-200201057	20001013
JP 2003512378	T2	20030402	JP 2001-531840	20001013
NZ 518119	A	20040227	NZ 2000-518119	20001013
AU 776250	B2	20040902	AU 2000-77873	20001013
US 6451804	B1	20020917	US 2000-693337	20001020
ZA 2002002540	A	20030630	ZA 2002-2540	20020328
NO 2002001781	A	20020418	NO 2002-1781	20020416
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):			MARPAT 134:326540	
G1				

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivs., such as I [R1 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.; R2 = vinyl, alkyl, halogen, heteroalkyl; R3 = alkyl, heteroalkyl, cycloalkyl, heterocyclyl, etc.; R4 = H, alkyl, etc.; n = 0-3], were prepared for pharmaceutical use. The compds. are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease. Thus, dihydropyrimido[4,5-d]pyrimidinone II (R = NHMe2CH2OH, R3 = Me) was prepared via a substitution reaction of H2NMe2CH2OH with sulfone I (R = SO2Me, R3 = Me) when combined and heated to 100-110° for 1 h. The prepared dihydropyrimido[4,5-d]pyrimidinone derivs. showed 50% p38 inhibitory activity at concns. < 10 μM.

IT 335651-19-9P 335651-20-2P 335651-24-6P
 335651-30-4P 335651-49-5P 335651-50-8P
 335651-51-9P 335651-53-1P 335651-55-3P
 335651-56-4P 335651-57-5P 335651-58-6P
 335651-59-7P 335651-60-0P 335651-61-1P
 335651-62-2P 335651-63-3P 335651-64-4P
 335651-65-5P 335651-66-6P 335651-67-7P
 335651-69-9P 335651-77-9P 335651-88-2P
 335651-89-3P 335651-93-9P 335651-94-0P
 335651-95-1P 335651-96-2P 335651-97-3P
 335651-98-4P 335651-99-5P 335652-00-1P
 335652-06-7P 335652-11-4P 335652-12-5P
 335652-13-6P 335652-14-7P 335652-16-9P
 335652-18-1P 335652-22-7P 335652-24-9P
 335652-26-1P 335652-30-7P 335652-32-9P
 335652-36-3P 335652-39-6P 335652-40-9P
 335652-41-0P 335652-44-3P 335652-46-5P
 335652-47-6P 335652-48-7P 335652-50-1P
 335652-55-6P 335652-56-7P 335652-58-9P
 335652-59-0P 335652-60-3P 335652-61-4P
 335652-62-5P 335652-63-6P 335652-64-7P
 335652-65-8P 335652-66-9P 335652-67-0P
 335652-68-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)

RN 335651-19-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-methylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335651-20-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxypropyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-24-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-30-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-49-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methylphenyl)-7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 335651-50-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-methylphenyl)-7-[[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 335651-51-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 335651-53-1 CAPLUS
CN 4-Piperidinamine, 1-(methylsulfonyl)-N-[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-55-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[1-[(2R)-2,3-dihydroxypropyl]-4-piperidinyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-56-4 CAPLUS
CN 1-Piperidinepropanenitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-57-5 CAPLUS
CN 1-Piperidineacetoneitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335651-58-6 CAPLUS
CN 1-Piperidineacetoneitrile, 4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-59-7 CAPLUS
CN 1-Piperidineacetamide, 4-[[2-amino-2-oxoethyl][5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-60-0 CAPLUS
CN 1-Piperidineacetamide, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-61-1 CAPLUS
CN 1-Piperidinepropanoic acid, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 335651-62-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[1-(2,2,2-trifluoroethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 335651-63-3 CAPLUS
CN 1-Piperidineacetoneitrile, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 335651-64-4 CAPLUS

CN 1-Piperidineacetamide, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 335651-65-5 CAPLUS

CN 1-Piperidineacetic acid, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 335651-66-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[methyl(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 335651-67-7 CAPLUS


CN 1-Piperidineacetamide, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 335651-89-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(1S)-2-hydroxy-1-methylethyl]amino]-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-93-9 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[trans-4-hydroxycyclohexyl]amino]-1-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-94-0 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-69-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 335651-77-9 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335651-88-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(ethoxymethyl)ethyl]-3,4-dihydro-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335651-95-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-96-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[trans-4-hydroxycyclohexyl]amino]-1-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-97-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335651-98-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-9CI] (CA INDEX NAME)


Relative stereochemistry.



RN 335651-99-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-N,N-dimethyl-2-oxo-9CI] (CA INDEX NAME)

Relative stereochemistry.




RN 335652-00-1 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335652-12-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-(2-methoxyethoxy)cyclohexyl)amino]-1-methyl-9CI] (CA INDEX NAME)


Relative stereochemistry.



RN 335652-13-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-(acetonyl)cyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl-9CI] (CA INDEX NAME)


Relative stereochemistry.



RN 335652-14-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-(2-propenyloxy)cyclohexyl)amino]-9CI] (CA INDEX NAME)

Relative stereochemistry.




RN 335652-16-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-(hydroxymethyl)cyclohexyl)amino]-1-methyl-9CI] (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-9CI] (CA INDEX NAME)



RN 335652-06-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-4-piperidinyl)-9CI] (CA INDEX NAME)


Relative stereochemistry.



RN 335652-11-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-methoxycyclohexyl)amino]-1-methyl-9CI] (CA INDEX NAME)


Relative stereochemistry.



RN 335652-18-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-(2S)-2,3-dihydroxypropoxy)cyclohexyl)amino]-3,4-dihydro-1-methyl-9CI] (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-22-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-(4-oxocyclohexyl)amino]-9CI] (CA INDEX NAME)




RN 335652-24-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(3-(dimethylamino)-2,2-dimethylpropyl)-3,4-dihydro-7-[(trans-4-(hydroxymethyl)-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl)amino]-1-methyl-9CI] (CA INDEX NAME)




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 335652-26-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-
 [(trans-4-hydroxycyclohexyl)amino]-1-phenylmethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-30-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-(hydroxyimino)cyclohexyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335652-32-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-
 [(trans-4-hydroxycyclohexyl)amino]-1-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-36-3 CAPLUS
 CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 8-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-44-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-
 [(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-46-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-47-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-39-6 CAPLUS
 CN Methanesulfonamide, N'-[[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-40-9 CAPLUS
 CN Sulfamide, N'-[[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-41-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335652-49-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-50-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)




RN 335652-55-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-(acetyloxy)cyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-56-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)cyclopentyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335652-58-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)cyclohexyl]amino]- (9CI) (CA INDEX NAME)




RN 335652-59-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-hydroxycyclohexyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 335652-60-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[cis-4-hydroxycyclohexyl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-61-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-(aminocarbonyl)oxy]cyclohexyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335652-65-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-(aminocarbonyl)oxy]cyclohexyl]amino]- (9CI) (CA INDEX NAME)




RN 335652-66-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[1,4-dioxaspiro[4.5]dec-8-ylamino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 335652-67-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-(aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-68-1 CAPLUS
 CN Sulfamide, N'-[trans-4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-62-5 CAPLUS
 CN Carbonic acid, trans-4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-63-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-[(aminocarbonyl)oxy]cyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-64-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[trans-4-[(methylamino)carbonyl]oxy]cyclohexyl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 335651-10-8P 335651-21-3P 335651-22-4P
 335651-23-5P 335651-25-7P 335651-26-8P
 335651-27-9P 335651-28-0P 335651-29-1P
 335651-31-5P 335651-32-6P 335651-33-7P
 335651-34-8P 335651-36-0P 335651-37-1P
 335651-38-2P 335651-39-3P 335651-40-6P
 335651-41-7P 335651-42-8P 335651-43-9P
 335651-44-0P 335651-45-1P 335651-46-2P
 335651-47-3P 335651-48-4P 335651-52-0P
 335651-54-2P 335651-68-8P 335651-70-2P
 335651-71-3P 335651-72-4P 335651-73-5P
 335651-74-6P 335651-75-7P 335651-76-8P
 335651-78-0P 335651-79-1P 335651-80-4P
 335651-81-5P 335651-82-6P 335651-83-7P
 335651-84-8P 335651-85-9P 335651-86-0P
 335651-87-1P 335651-90-6P 335651-91-7P
 335651-92-8P 335652-02-3P 335652-04-5P
 335652-08-9P 335652-10-3P 335652-20-5P
 335652-28-3P 335652-34-1P 335652-37-4P
 335652-38-5P 335652-42-1P 335652-43-2P
 335652-45-4P 335652-49-8P 335652-51-2P
 335652-52-3P 335652-53-4P 335652-54-5P
 335652-57-8P 335652-69-2P 335652-70-3P
 335652-71-6P 335652-72-7P 335652-73-8P
 335652-74-9P 335652-75-0P 335652-76-1P
 335652-77-2P 335652-78-3P 335652-79-4P
 335652-80-7P 335652-81-8P 335652-82-9P
 335652-83-0P 335652-84-1P 335652-85-2P
 335652-86-3P 335652-87-4P 335652-88-5P
 335652-90-9P 335652-91-0P 335652-92-1P
 335652-93-2P 335652-94-3P 335652-95-4P
 335652-96-5P 335652-97-6P 335652-98-7P
 335653-00-6P 335653-00-6P 335653-01-5P
 335653-02-6P 335653-03-7P 335653-04-8P
 335653-05-9P 335653-06-0P 335653-07-1P
 335653-08-2P 335653-09-3P 335653-10-6P
 335653-11-7P 335653-12-8P 335653-13-9P
 335653-16-2P 335653-17-3P 335653-18-4P
 335653-19-5P 335653-20-8P 335653-21-9P
 335653-22-0P 335653-23-1P 335653-24-2P
 335653-25-3P 335653-26-4P 335653-27-5P
 335653-28-6P 335653-29-7P 335653-30-8P
 335653-31-1P 335653-32-2P 335653-33-3P
 335653-34-4P 335653-35-5P 335653-36-6P
 335653-37-7P 335653-38-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of alkylamino substituted pyrimidino[4,5-d]pyrimidines for
pharmaceutical use as inhibitors of p38 protein kinase)

RN 335651-18-8 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxyethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-21-3 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(1S)-2-hydroxy-1-methylethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335651-22-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-23-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-dihydroxypropyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335651-28-0 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-29-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-31-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-32-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)-2-methylpropyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-25-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-26-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[3-hydroxybutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-27-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[2-hydroxybutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335651-33-7 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)butyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-34-8 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[trans-4-hydroxycyclohexyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335651-36-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)pentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-37-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
[[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-38-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-39-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)cyclopentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-40-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-41-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-42-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[2-(1-piperidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 335651-43-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[3-(1-piperidinyl)propyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-44-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 335651-45-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[3-(4-morpholinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 335651-46-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[tetrahydro-1,1-dioxido-3-thienyl]amino]- (9CI) (CA INDEX NAME)




RN 335651-47-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-48-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 335651-52-0 CAPLUS
CN 1-Piperidineacetamide, 4-[[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-54-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[[1-(2-hydroxyethyl)-4-piperidinyl]amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-68-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(2,2-trifluoroethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 335651-70-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2,2-dimethylpropyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-71-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2,2-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-72-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2-dimethylamino)ethyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2-hydroxypropyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-78-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 335651-79-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-80-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-73-5 CAPLUS
CN Acetamide, N-[2-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 335651-74-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-75-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)pentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-76-8 CAPLUS


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 335651-81-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335651-82-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)-2-methylpropyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-83-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[[1-(hydroxymethyl)-2-methylpropyl]amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335651-84-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[[[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335651-85-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[[[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-3-(2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-86-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[[[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-87-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[[[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-3-(2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-90-6 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Absolute stereochemistry.



RN 335652-04-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-3-piperidinyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-08-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-10-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(trans-4-methoxycyclohexyl)methylamino]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-91-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[(1S,2S)-2-aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-92-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[(1R,2R)-2-aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-02-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 335652-20-5 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335652-28-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(trans-4-hydroxycyclohexyl)amino]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-34-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-37-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-38-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-42-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-51-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-2-hydroxy-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-52-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-53-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2-ethoxy-1-ethoxymethyl)ethyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 335652-54-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335652-43-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 335652-45-4 CAPLUS
 CN Butanoic acid, 3-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335652-49-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


[[1R]-1-(hydroxymethyl)propyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-57-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-(formyloxy)cyclohexyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-69-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1R]-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335652-70-5 CAPLUS
 CN Methanesulfonamide, N-[trans-4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335652-71-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-72-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1R,2S]-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 335652-73-8 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
hydroxy-1-methylethyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 335652-74-9 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxypropyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-75-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335652-76-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)cyclohexyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-77-2 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[3-(hydroxymethyl)-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-78-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[4-oxocyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335652-79-4 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-(hydroxymethyl)cyclohexyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-80-7 CAPLUS

CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 8-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-81-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[trans-4-(2-propenyloxy)cyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-82-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[trans-4-(2-methoxycyclohexyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-83-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[trans-4-(2-methoxyethoxy)cyclohexyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-84-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-(acetyloxycyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-85-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[trans-4-(2,3-dihydroxypropoxy)cyclohexyl]amino]-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 335652-86-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-(aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 335652-87-4 CAPLUS
CN Methanesulfonamide, N-[[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-88-5 CAPLUS
CN Sulfamide, N'-[[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-90-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[[trans-4-hydroxycyclohexyl]amino]-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 335652-91-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-92-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-methylphenyl)-7-[[1-(phenylmethyl)-4-piperidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 335652-96-5 CAPLUS
 CN 1-Piperidinepropanoic acid, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-97-6 CAPLUS
 CN 1-Piperidineacetamide, 4-[(2-amino-2-oxoethyl)[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-98-7 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 335652-93-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[1-[(2R)-2,3-dihydroxypropyl]-4-piperidinyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 335652-94-3 CAPLUS
 CN 1-Piperidinepropanenitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-95-4 CAPLUS
 CN 1-Piperidineacetoneitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Piperidineamine, 1-(methylsulfonyl)-N-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-99-8 CAPLUS
 CN 1-Piperidineacetoneitrile, 4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335653-00-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 335653-01-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-(diethylamino)ethyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-02-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-(dimethylamino)ethyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 335653-05-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-(diethylamino)ethyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-N,N-dimethyl-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-06-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 335653-03-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-(diethylamino)ethyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 335653-04-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-ethoxy-1-(ethoxymethyl)ethyl)-3,4-dihydro-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 335653-07-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-(diethylamino)ethyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-08-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-(diethylamino)ethyl)-3,4-dihydro-7-[[tetrahydro-2H-pyran-4-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-09-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-(diethylamino)ethyl)-3,4-dihydro-7-[[1-(hydroxymethyl)cyclopentyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 335653-10-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)cyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-11-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[methyl(1-methyl-4-piperidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-12-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(cis-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[1-(2,2,2-trifluoroethyl)-4-piperidinyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 335653-18-4 CAPLUS


CN 1-Piperidineacetonitrile, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-19-5 CAPLUS

CN 1-Piperidineacetamide, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 335653-13-9 CAPLUS


CN 1-Piperidineacetamide, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-16-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[4-hydroxycyclohexyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335653-17-3 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335653-20-8 CAPLUS


CN 1-Piperidineacetamide, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-21-9 CAPLUS

CN 1-Piperidineacetic acid, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335653-22-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[trans-4-hydroxycyclohexyl]amino]-1-[2-(methylthio)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335653-23-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[3-(dimethylamino)-2,2-dimethylpropyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335653-24-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335653-27-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 335653-28-6 CAPLUS
 CN Sulfamide, N'-[trans-4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 335653-29-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-ylamino)-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-25-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 335653-26-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-(hydroxymethyl)cyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-30-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-(hydroxymethyl)cyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-31-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[trans-4-hydroxycyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-32-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 335653-33-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-(acetyloxy)cyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 335653-34-4 CAPLUS
 CN Carbonic acid, trans-4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 335653-38-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[trans-4-(hydroxycyclohexyl)amino]-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 335653-41-3P 335653-50-2P 335653-62-0P
 335653-63-9P 335653-74-2P 335653-75-3P
 335653-76-4P 335653-77-5P 335653-78-6P
 335653-79-7P 335653-80-0P 335653-84-4P
 335653-85-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)

RN 335653-41-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[1,5,6,7-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335653-35-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-[[aminocarbonyl]oxy]cyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335653-36-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[trans-4-[[methylamino]carbonyl]oxy]cyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RN 335653-37-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[trans-4-(hydroxycyclohexyl)amino]-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335653-58-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 335653-62-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335653-63-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[4-piperidinylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 335653-74-2 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Sulfamide, N'-[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-7-oxo-8-[[[2-(trimethylsilyl)ethoxymethyl]pyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335653-75-3 CAPLUS
 CN Butanoic acid, 3-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 335653-76-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[trans-4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]cyclohexyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335653-77-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[trans-4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]cyclohexyl]amino]-3,4-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 [[tris(1-methylethyl)silyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335653-84-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-[[[2-(trimethylsilyl)ethoxymethyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335653-85-5 CAPLUS
 CN Methanesulfonamide, N'-[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-7-oxo-8-[[[2-(trimethylsilyl)ethoxymethyl]pyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335653-78-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-1(2H)-acetoneitrile, 3-(2-chlorophenyl)-7-[[trans-4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]cyclohexyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335653-79-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-1(2H)-acetic acid, 3-(2-chlorophenyl)-7-[[trans-4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]cyclohexyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335653-80-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[trans-4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]cyclohexyl]amino]-3,4-dihydro-1-(2-

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:300720 CAPLUS
 DOCUMENT NUMBER: 134:311223
 TITLE: Preparation of alkylamino substituted bicyclic nitrogen heterocycles for pharmaceutical use as inhibitors of p39 protein kinase
 INVENTOR(S): Dunn, James Patrick; Goldstein, David Michael; Harris, William; Smith, Ian Edward David; Welch, Teresa Rosanne
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029041	A1	20010426	WO 2000-EP10077	20001013
W: AB, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2388140	AA	20010426	CA 2000-2388140	20001013
BR 2000014973	A	20020716	BR 2000-14973	20001013
TR 200201058	T2	20020722	TR 2002-200201058	20001013
EP 1226144	A1	20020731	EP 2000-972755	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003512377	T2	20030402	JP 2001-531839	20001013
AU 776695	B2	20040916	AU 2001-11375	20001013
US 6642241	B1	20031104	US 2000-693364	20001020
ZA 2002002603	A	20030703	ZA 2002-2603	20020403
NO 2002001783	A	20020416	NO 2002-1783	20020416
PRIORITY APPL. INFO.:				
US 1999-160804P			P 19991021	
US 2000-213718P			P 20000622	
WO 2000-EP10077			W 20001013	

OTHER SOURCE(S): MARPAT 134:311223
 G1




AB Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivs., such as I [R1 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.; R2 = vinyl, R3 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.; R4 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.]


- L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
alkyl, halogen, heteroalkyl; R3 = alkyl, heteroalkyl, cycloalkyl, heterocyclyl, etc.; n = 0-3], were prepd. for pharmaceutical use as inhibitors of p38 protein kinase for the treatment of conditions such as arthritis, Crohn's disease, obstructive pulmonary disease, or irritable bowel syndrome.. Thus, dihydropyrimido[4,5-d]pyrimidinone II (R = NHCHMe2, R3 = CH2CO2H) was prepd. via a substitution reaction of H2NCHMe2 with sulfone II (R = SO2CH2Ph, R3 = CH2CO2Et) when combined and heated to 90-100° for 1 h. The prepd. dihydropyrimido[4,5-d]pyrimidinone derivs. showed p38 50% inhibitory activity at concns. < 10 µM.
- IT 335318-15-5P 335318-19-9P 335318-22-4P
335318-39-3P 335318-40-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)
- RN 335318-15-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-hydroxyethyl)-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




- RN 335318-19-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



- RN 335318-22-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




- RN 335318-10-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-methoxyethyl)-7-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


- RN 335318-11-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

- RN 335318-12-2 CAPLUS


- L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



- RN 335318-39-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




- RN 335318-40-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-methoxyethyl)-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



- IT 335318-09-7P 335318-10-0P 335318-11-1P
335318-12-2P 335318-16-6P 335318-17-7P
335318-18-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


- L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-hydroxyethyl)-7-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


- RN 335318-16-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2S)-2,3-dihydroxypropyl]-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 335318-17-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2S)-2,3-dihydroxypropyl]-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335318-18-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethylamino)-1-[2-(1-piperidinylethyl)]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 335318-27-9P 335318-33-7P 335318-38-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)

RN 335318-27-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethylamino)-1-[2-[(tris(1-methylethyl)silyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 335318-33-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[[4(R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-3,4-dihydro-7-[(1-methylethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:291041 CAPLUS

DOCUMENT NUMBER: 132:308352

TITLE: Preparation of pyrimidopyrimidinones as T-cell

cytosine kinase inhibitors

INVENTOR(S): Harris, William; Hill, Christopher; Huw; Smith, Ian

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024744	A1	20000504	WO 1999-EP7675	19991013
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2347474	AA	20000504	CA 1999-234744	19991013
BR 9914677	A	20010717	BR 1999-14677	19991013
EP 1123295	A1	20010816	EP 1999-953796	19991013
EP 1123295	B1	20040929		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200101102	T2	20020121	TR 2001-200101102	19991013
JP 2002528455	T2	20020903	JP 2000-578314	19991013
JP 3593035	B2	20041124		
NZ 510760	A	20030829	NZ 1999-510760	19991013
AU 769989	B2	20040212	AU 2000-10363	19991013
AT 277931	E	20041015	AT 1999-953796	19991013
US 6150373	A	20001121	US 1999-422451	19991021
ZA 2001002652	A	20020930	ZA 2001-2652	20010330
HR 2001000274	A1	20020630	HR 2001-274	20010412
NO 2001001929	A	20010419	NO 2001-1929	20010419
HK 1041463	A1	20041224	HK 2002-103084	20020424
PRIORITY APPL. INFO.:			GB 1998-23277	A 19981023
			GB 1999-20044	A 19990824
			WO 1999-EP7675	W 19991013
OTHER SOURCE(S):	MARPAT 132:308352			
GI				




AB Title compds. [I: R1 = NH2, alkylamino, (hetero)aryl(alkyl)amino; R2 =

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335318-38-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethylamino)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


alkyl (hetero)aryl(alkyl); R3 = H, alkyl, (hetero)aryl(alkyl), cycloalkenyl] were prepd. Thus, Et 4-chloro-2-methylthiopyrimidine-5-carboxylate was aminated by MeNH2 and the product converted to the aldehyde which was condensed with 2,6-Cl2C6H3NH2 to give 2,6-Cl2C6H3NHCH2ZNMMe (Z = 2-methylthiopyrimidine-5,4-diyl). The latter was cyclized with COCl2 and the product oxidized to give I (R2 = 2,6-Cl2C6H3NHCH2, R3 = Me) (II: R1 = SO2Me) which was aminated by 4-(H2N)C6H4OCH2CH2NMe2 (prepn. given) to give II (R1 = 4-(Et2NCH2CH2O)C6H4NH). Data for biol. activity of I were given.

266312-86-1P	266312-87-2P	266312-88-3P
266312-93-0P	266312-94-1P	266312-95-2P
266312-97-4P	266312-98-5P	266312-99-6P
266313-00-2P	266313-01-3P	266313-02-4P
266313-03-5P	266313-04-6P	266313-05-7P
266313-06-8P	266313-07-9P	266313-08-0P
266313-09-1P	266313-10-4P	266313-11-5P
266313-12-6P	266313-13-7P	266313-14-8P
266313-15-9P	266313-16-0P	266313-17-1P
266313-18-2P	266313-19-3P	266313-20-6P
266313-21-7P	266313-22-8P	266313-23-9P
266313-24-0P	266313-25-1P	266313-27-3P
266313-29-5P	266313-30-8P	266313-31-9P
266313-32-0P	266313-33-1P	266313-34-2P
266313-35-3P	266313-36-4P	266313-37-5P
266313-38-6P	266313-39-7P	266313-40-0P
266313-41-1P	266313-42-2P	266313-43-3P
266313-44-4P	266313-45-5P	266313-46-6P
266313-47-7P	266313-48-8P	266313-49-9P
266313-50-2P	266313-51-3P	266313-52-4P
266313-53-5P	266313-54-6P	266313-55-7P
266313-56-8P	266313-57-9P	266313-58-0P
266313-59-1P	266313-60-4P	266313-61-5P
266313-62-6P	266313-63-7P	266313-64-8P
266313-65-9P	266313-66-0P	266313-67-1P
266313-68-2P	266313-69-3P	266313-70-6P
266313-71-7P	266313-73-9P	266313-74-0P
266313-75-1P	266313-76-2P	266313-77-3P
266313-78-4P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidopyrimidinones as T-cell cytosine kinase inhibitors)


RN 266312-86-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-(2-diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266312-87-2 CAPLUS


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266312-88-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 266312-93-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266312-94-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CMF C2 H F3 O2




RN 266312-98-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 266312-99-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-(fluorophenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-00-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-01-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[4-methoxyphenyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266312-95-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 266312-97-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-(3-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 266312-96-3
 CMF C30 H31 Cl2 N7 O2




CM 2

CRN 76-05-1


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-02-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(dimethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-03-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[4-(2-hydroxyethyl)phenyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-04-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 266313-05-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[2,4-dimethoxyphenyl]methyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-06-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-07-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-(cyclohexylamino)-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-08-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-13-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[2-(4-aminophenyl)ethyl]amino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-14-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]methyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-15-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(2,6-dimethylphenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-16-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 266313-09-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 266313-10-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(cyclohexylmethyl)amino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-11-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-(1-naphthalenylamino)-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-12-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(aminomethyl)phenyl]methyl]amino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-17-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 266313-18-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 266313-19-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-20-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[4-(methoxyphenyl)methyl]amino]-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-21-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-22-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(2,6-difluorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-23-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)





RN 266313-29-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-(2-cyclohexen-1-yl)-3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-30-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-31-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,5-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-24-0 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,6-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266313-25-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-27-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


RN 266313-32-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-33-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-methoxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-34-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-hydroxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-35-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-3-[(4-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 266313-36-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2-bromophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 266313-37-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-38-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,6-dimethylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-39-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-[2-chloro-


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 dichlorophenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-43-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-(2-diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 266313-44-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[3-(2-hydroxy-1,1-dimethylethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-45-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-1,1-dimethylethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 4-(trifluoromethyl)phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-40-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-41-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-chloro-6-methylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-42-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,5-


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-46-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[[4-methoxyphenyl]amino]- (9CI) (CA INDEX NAME)




RN 266313-47-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[[4-hydroxyphenyl]amino]- (9CI) (CA INDEX NAME)




RN 266313-48-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-49-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[(4-hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-50-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[(4-hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-51-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(4-aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl)methyl]- (9CI) (CA INDEX NAME)



RN 266313-55-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-ethoxyphenyl)amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-56-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-57-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-(2-(methylamino)ethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-52-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[(1-naphthalenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-53-5 CAPLUS
 CN Benzoic acid, 3-[[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 266313-54-6 CAPLUS
 CN Benzoic acid, 3-[[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-58-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-59-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-60-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminomethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-61-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-(methylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-62-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-63-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-(cyclohexylmethyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-67-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 266313-68-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-69-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-64-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[4-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-65-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[4-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-66-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-70-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)



RN 266313-71-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-2-methylpropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-73-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-[1-(aminomethyl)-1-ethylpropyl]phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 266313-72-8
CMF C30 H30 Cl2 N6 O


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 266313-74-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(3-aminopropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-75-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-(2-diethylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 266314-05-0P 266314-38-9P 266314-39-0P
266314-40-3P 266314-45-0P 266314-46-9P
266314-47-0P 266314-48-1P 266314-49-2P
266314-51-6P 266314-62-9P 266314-63-0P
266314-71-0P 266314-78-7P 266314-79-8P
266314-83-4P 266314-84-5P 266314-86-7P
266314-91-4P 266314-92-5P 266314-93-6P
266315-34-0P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)


RN 266314-05-0 CAPLUS
CN Benzeneacetic acid, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 266314-38-9 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-76-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-(4-morpholinyl)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-77-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-1-[3-[2-(1-piperazinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 266313-78-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(2-furanylmethyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 266314-39-0 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,6-dimethylphenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-40-3 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-chloro-4-(trifluoromethyl)phenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-45-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-1-[3-[2-[[[1,1-dimethylethyl]diphenyl]oxy]ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266314-46-9 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-[2-chloro-6-methylphenyl]-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-47-0 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[[3-[[3-(2-chloro-6-methylphenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266314-62-9 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[[3-[[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 266314-63-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)-1-[3-[[[tetrahydro-2H-pyran-2-yl]oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 266314-71-0 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[[3-[[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 266314-48-1 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[[3-[[3-(2,5-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-49-2 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-[3-[2-[[[1,1-dimethylethyl]diphenylsilyl]oxy]-1,1-dimethylethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-51-6 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[[3-[[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266314-78-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-[3-[2-[[[1,1-dimethylethyl]diphenylsilyl]oxy]ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-79-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266314-83-4 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-84-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266314-86-7 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[4-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-91-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-[3-[2-[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266314-92-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 266314-93-6 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266315-34-8 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[3-[3-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]propyl]- (9CI)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:764041 CAPLUS
 DOCUMENT NUMBER: 132:22971
 TITLE: Preparation of oxopyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors
 INVENTOR(S): Dobrusin, Ellen Myra; Hamby, James Marino; Kramer, James Bernard; Schroeder, Mel Conrad; Showalter, Howard Daniel; Hollis; Toogood, Peter; Trumpf-Kallmeyer, Susanne A.
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961444	A2	19991202	WO 1999-US10187	19990510
WO 9961444	A3	20000203		
W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2329703	AA	19991202	CA 1999-2329703	19990510
AU 9940734	A1	19991213	AU 1999-40734	19990510
AU 763839	B2	20030731		
BR 9911590	A	20010213	BR 1999-11590	19990510
EP 1080092	A2	20010307	EP 1999-924165	19990510
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200003429	T2	20010723	TR 2000-200003429	19990510
JP 200216327	T2	20020604	JP 2000-550849	19990510
KE 200000706	A	20020617	KE 2000-706	19990510
NZ 508268	A	20040227	NZ 1999-508268	19990510
ZA 2000006536	A	20020211	ZA 2000-6536	20001110
BG 104960	A	20011031	BG 2000-104960	20001117
HR 2000000799	A1	20010630	HR 2000-799	20001120
NO 2000005928	A	20001123	NO 2000-5928	20001123
HK 1039483	A1	20040618	HK 2001-107828	20011108
US 2004044012	A1	20040304	US 2003-638848	20030811
PRIORITY APPL. INFO.:			US 1998-86708P	P 19980526
			US 1999-126158P	P 19990325
OTHER SOURCE(S):		MARPAT 132:22971	WO 1999-US10187	W 19990510
GI			US 2000-623737	A3 20000907

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. [I; G = NR2 or CHR2; R = NHR1' or SOO-2R1; R1, R2 = H, (cyclo)alkyl, (un)substituted PH, -pyridyl, etc.; R3 = groups cited for R1, OH, alkoxy(carbonyl), etc.; R4 = H; R3R4 = bond; R8, R9 = H, halo, NH2, alkoxy(carbonyl), etc.; X = O, S, (alkyl)imino, etc.; Z = N or CH] were prepared as cyclin-dependant and tyrosine kinase inhibitors. Thus, 5-aminomethyl-4-cyclopentylamino-2-methylthiopyrimidine (preparation given)

was cyclocondensed with 1,1'-carbonyldiimidazole and the oxidized product aminated by 4-(MeO)CGH4NH2 to give I [G = cyclopentylimino, R = 4-(MeO)CGH4NH, R3 = R4 = R8 = R9 = H, X = O]. Data for biol. activity of I were given.

IT 251370-13-5P 251370-14-6P 251370-15-7P
 251370-16-8P 251370-17-9P 251370-18-0P
 251370-19-1P 251370-20-4P 251370-21-5P
 251370-22-6P 251370-23-7P 251370-24-8P
 251370-25-9P 251370-26-0P 251370-27-1P
 251370-28-2P 251370-29-3P 251370-30-6P
 251370-31-7P 251370-32-8P 251370-33-9P
 251370-34-0P 251370-35-1P 251370-36-2P
 251370-37-3P 251370-38-4P 251370-39-5P
 251370-40-6P 251370-41-7P 251370-42-8P
 251370-43-9P 251370-44-0P 251370-45-1P
 251370-46-2P 251370-47-3P 251370-48-4P
 251370-49-5P 251370-50-6P 251370-51-7P
 251370-52-8P 251370-53-9P 251370-54-0P
 251370-55-1P 251370-56-2P 251370-57-3P
 251370-58-4P 251370-59-5P 251370-60-6P
 251370-61-7P 251370-62-8P 251370-63-9P
 251370-64-0P 251370-65-1P 251370-66-2P
 251370-67-3P 251370-68-4P 251370-69-5P
 251370-70-6P 251370-71-7P 251370-72-8P
 251370-73-9P 251370-74-0P 251370-75-1P
 251370-76-2P 251370-77-3P 251370-78-4P
 251370-79-5P 251370-80-6P 251370-81-7P
 251370-82-8P 251370-83-9P 251370-84-0P
 251370-85-1P 251370-86-2P 251370-87-3P
 251370-88-4P 251370-89-5P 251370-90-6P
 251370-91-7P 251370-92-8P 251370-93-9P


RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines)

as inhibitors of cellular proliferation)


RN 251370-13-5 CAPLUS

CN Piperazine, 1-(aminoacetyl)-4-[[6-(3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251370-14-6 CAPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[[6-(2-chloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 251370-15-7 CAPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 251370-16-8 CAPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[[6-(3,5-dimethoxy-2-methylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251370-17-9 CAPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[[6-(3,5-dimethoxy-2,6-dimethylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 251370-18-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(2-(diethylamino)ethoxy)phenyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-19-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-(2-(diethylamino)ethoxy)phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251370-20-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[[4-(2-(diethylamino)ethoxy)phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-21-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(2-(diethylamino)ethoxy)phenyl]amino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-22-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(2-(diethylamino)ethoxy)phenyl]amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251370-26-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-27-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-28-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-29-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251370-23-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-24-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-(diethylamino)butyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-25-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[[4-(diethylamino)butyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251370-30-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-31-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-32-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 251370-33-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-dichloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-34-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-(diethylamino)butyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-35-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-36-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251370-66-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)




RN 251370-67-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-(diethylamino)ethoxy]phenyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)




RN 251370-68-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-(3,5-dimethoxyphenyl)-1-ethyl-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251370-37-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-38-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-39-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-40-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251371-07-0 CAPLUS
 CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-08-1 CAPLUS
 CN Benzamide, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 251371-09-2 CAPLUS
 CN Benzamide, 3-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 251371-10-5 CAPLUS
 CN Benzoic acid, 3-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251371-11-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(ethoxyamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-12-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-7-[[4-[2-(ethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-13-8 CAPLUS
CN Benzamide, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251371-17-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-7-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-18-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-19-4 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251371-14-9 CAPLUS
CN Benzamide, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 251371-15-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-16-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251371-20-7 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-21-8 CAPLUS
CN Benzaldehyde, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 251371-22-9 CAPLUS
CN Benzaldehyde, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 251371-83-2 CAPLUS


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251371-84-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[2-[(4-pyridinylmethyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-85-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-86-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-87-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251371-92-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-93-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-(diethylamino)propyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



IT 251372-03-9P 251372-05-1P
 RL: SPN (Synthetic preparation): PREP (Preparation)
 (preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines


as inhibitors of cellular proliferation)

RN 251372-03-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-7-[[4-(4-methyl-1-piperazinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 251372-05-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-[2-


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251371-88-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-(diethylamino)propyl]amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251371-88-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[2-[(4-pyridinylmethyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-90-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-91-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (diethylamino)ethoxy]phenyl]amino]-3-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:209801 CAPLUS
 DOCUMENT NUMBER: 130:338080
 TITLE: A solid phase approach to substituted pyrimidines and their conversion into condensed heterocycles for potential use in combinatorial chemistry
 AUTHOR(S): Srivastava, Sanjay K.; Haq, W.; Chauhan, P. M. S.
 CORPORATE SOURCE: Divisions of Medicinal Chemistry and Biopolymers, Central Drug Research Institute, Lucknow, 226001, India
 SOURCE: Combinatorial Chemistry and High Throughput Screening (1999), 2(1), 33-37
 CODEN: CCHSFU; ISSN: 1386-2073
 PUBLISHER: Bentham Science Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A novel general synthesis of substituted pyrimidines has been carried out on a solid support. The C-atoms carrying the cyano, amino, carboxamido, as well as the anchoring site have been exploited to generate libraries of compds. Synthesis of 2,5,6-trisubstituted pyrimidines was carried out by nucleophilic displacement of the anchor by various amines. Further investigations were directed toward the solid phase synthesis of pyrimido[4,5-d]pyrimidines.
 IT 224575-96-6P
 RL: SPN (Synthetic preparation); PREP (Preparation) (solid-phase synthesis of pyrimidines and their conversion into condensed heterocycles)
 RN 224575-96-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-(cyclohexylamino)-3-phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1991:408712 CAPLUS
 DOCUMENT NUMBER: 115:8712
 TITLE: Synthesis of 2,4-diamino-5-acetyl(ethoxycarbonyl)pyrimidines from β -dicarbonyl compounds and dicyandiamide and their application for the construction of pyrimido[4,5-d]pyrimidine system
 AUTHOR(S): Dorokhov, V. A.; Gordeev, M. F.; Komkov, A. V.; Bogdanov, V. S.
 CORPORATE SOURCE: Inst. Org. Khim. im. Zelinskogo, Moscow, USSR
 SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1991), (1), 159-64
 CODEN: IASKA6; ISSN: 0002-3353
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 115:8712
 GI



AB The reaction of $\text{MeCOCH}_2\text{COMe}$ or $\text{ROOCH}_2\text{COR1}$ ($\text{R} = \text{Me}$, Ph ; $\text{R1} = \text{Me}$, OEt) with $\text{HZNC(NH}_2\text{):NCN}$ in the presence of Ni(OAc)_2 gives pyrimidines I. Regiospecific annelation of I. (after protection of the 2-NH₂ group) with PhNCO or $(\text{MeO})_2\text{CHNMe}_2$ gives pyrimidopyrimidines, e.g., II, III, IV.
 IT 134221-31-1P 134221-32-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 134221-31-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 134221-32-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-3,5-diphenyl- (9CI) (CA INDEX NAME)

